<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F74A7E46-F1D9-421A-BF10-4EFDAD81DFE7"><gtr:id>F74A7E46-F1D9-421A-BF10-4EFDAD81DFE7</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:surname>Killick</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1AD81458-D7F1-4E1D-9D49-DA319E1C5D6C"><gtr:id>1AD81458-D7F1-4E1D-9D49-DA319E1C5D6C</gtr:id><gtr:firstName>Diane</gtr:firstName><gtr:surname>Hanger</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0400050"><gtr:id>878F3526-F439-459D-8ED1-2AF0F85D9015</gtr:id><gtr:title>Functional proteomics for elucidating the mechanism of amyloid toxicity</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400050</gtr:grantReference><gtr:abstractText>Alzheimer?s disease is a devastating condition that affects up to three quarters of a million people in the UK, representing ~1% of the population. Since this disease affects primarily older people and the number of people reaching an advanced age continues to increase each year, the proportion of affected people is rising. Some treatments for Alzheimer?s disease now exist, but all of these treat only the symptoms, and not the cause so that after a while the treatments fail and patients continue to deteriorate as nerve cells die and dementia worsens. One of the major changes in Alzheimer brain is the presence of neuritic or senile plaques, comprised mainly of a protein called amyloid. A second change is the appearance of tangles containing a different protein called tau. However, this project focuses on amyloid protein since the deposits of amyloid present in plaques are abnormal and it is important to determine how this abnormal form is generated from its precursor protein. A major site for the production of amyloid is in specialised areas on the surface of the nerve cell called lipid rafts. These rafts contain concentrations of molecules including proteins and cholesterol that ?float? around in the cell surface in a sea of fats. Our hypothesis is that changing the amount of cholesterol influences the composition of the proteins normally present in lipid rafts and this affects the production of amyloid protein. Such changes could trigger a series of signalling events through the cell that leads to nerve cell death and ultimately dementia. Understanding the processes involved in the regulation of amyloid production via cholesterol is the first step towards discovering new pathways involved in Alzheimer?s disease so that new targets can be identified. If changes in lipid rafts can be influenced by drug treatment, then this work will inform the development of new drugs to treat Alzheimer?s disease. Some drugs aimed at preventing the abnormalities in amyloid are in development, however these are aimed at different pathways and until we have an effective treatment there is still a need to find new drug targets to combat Alzheimer?s disease.
Key research findings generated from researchers in the Neurodegeneration Interdisciplinary Research Group are posted on the Institute Psychiatry website. This information is accessible to all and therefore provides the lay public with information about the progress of our research. Topics of special interest are reported as press releases whenever appropriate.</gtr:abstractText><gtr:technicalSummary>The deposition of amyloid beta-peptide (Abeta) in the brain is the probable trigger for neurodegeneration in Alzheimer?s disease. However, although there is evidence of rapid signal transduction changes in neurons in response to Abeta exposure, the molecular mechanisms that result in neuronal cell death remain unknown. We have shown that activation of the tyrosine kinase, fyn, occurs within minutes of application of Abeta to neurons in culture and the amount of fyn associated with lipid rafts increases in response to Abeta; neurons from fyn-/- mice are resistant to Abeta toxicity. Lipid rafts are the probable location at which Abeta triggers the neurotoxic response and this may partially explain why lowering cholesterol is protective against developing Alzheimer?s disease. We propose to apply proteomics to investigate the function of changes in abundance of lipid raft proteins and post-translation changes in these proteins in the response of neurons in culture to Abeta exposure. We shall also investigate how lowering the cholesterol content affects the susceptibility of neurons to Abeta and the corresponding protein changes by proteomics. We shall investigate by proteomics the Abeta-induced changes in lipid raft proteins in neurons from fyn-/- mice with the aim of identifying which proteins are critical to the neurotoxic response. The results of these investigations will increase knowledge of the initiating mechanisms of neurodegeneration and may lead to the identification of new therapeutic targets for Alzheimer?s disease.</gtr:technicalSummary><gtr:fund><gtr:end>2008-07-03</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-04-04</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>565822</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>9774E098-0AB5-4C9E-B018-32B46B50B1DC</gtr:id><gtr:impact>Presentations to members of the public at the MRC Centre for Neurodegeneration Open Day, King's College London

Presentation of information</gtr:impact><gtr:outcomeId>707D4A7DB39</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PSP Bulletin</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>40E3284B-2CA8-4AC6-82B3-7531563FF197</gtr:id><gtr:impact>Regular contributions describing progress to the Progressive Supranuclear Palsy Association Bulletin

Not known</gtr:impact><gtr:outcomeId>A7967548589</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Report</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CF44AB89-ED39-4AD0-BE6A-CDECAE2412B4</gtr:id><gtr:impact>Article provided on work in my reseearch group which was published in the Institute of Psychiatry Annual Research Report

Not known</gtr:impact><gtr:outcomeId>05F35071E77</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D92CC9AF-CC1C-4D96-BD18-5C825A6AA994</gtr:id><gtr:impact>Demonstrations at MRC Centre for Neurodegeneration Research Open Day

Not known</gtr:impact><gtr:outcomeId>CB406124F2E</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BRC project grant</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>030D71E6-F08A-49CC-811A-6CC40F9BB196</gtr:id><gtr:outcomeId>WbXx8pyTbe30</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>430008</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC strategic grant</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>26BEC972-317A-43CC-99A9-767C0C2395B3</gtr:id><gtr:outcomeId>C02CF9006C50</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>32200</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PSP project grant/Progressive supranuclear palsy association</gtr:description><gtr:fundingOrg>Progressive Supranuclear Palsy Association (PSPA)</gtr:fundingOrg><gtr:id>CD9C28C8-A47D-487E-9A0A-45A8AFA91EC2</gtr:id><gtr:outcomeId>j3dK3HL6SU30</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>104610</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>RS industry fellowship</gtr:description><gtr:fundingOrg>The Royal Society</gtr:fundingOrg><gtr:id>A239D8B7-4787-4F99-A54E-B8764C0B8711</gtr:id><gtr:outcomeId>ffmsCAsFjVX0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>148185</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Project Grant</gtr:description><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>1054A9A3-3C16-41A5-93E3-C93F5277CCDF</gtr:id><gtr:outcomeId>394DE52B0CB0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>7494</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Psychiatry Research Trust</gtr:department><gtr:description>PRT brain banking research funds/Psychiatry Research Trust</gtr:description><gtr:fundingOrg>King's College London</gtr:fundingOrg><gtr:id>F288141B-6AF5-4FB9-ACD8-78A653FDE51F</gtr:id><gtr:outcomeId>fwmU9LbBjSj0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Protocol for quantitative proteomics of cellular membranes
and membrane rafts</gtr:description><gtr:id>AAF90251-F3D6-4CFB-A6F9-6BF1BB422F30</gtr:id><gtr:impact>Publications</gtr:impact><gtr:outcomeId>p3gD1dE7Yab</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Stacking gel method</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Antibodies produced to tau</gtr:description><gtr:id>FD04E3AB-CC64-41DE-B136-8252CC23BB2A</gtr:id><gtr:impact>The antibodies work well against the antigen to which they were raised. their suitability in other applications will be assessed</gtr:impact><gtr:outcomeId>Dd2SyxS5r9o</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Tau antibodies</gtr:title><gtr:type>Antibody</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Proteome Sciences plc</gtr:companyName><gtr:description>http://www.proteomics.com/</gtr:description><gtr:id>B43029EE-DC77-422B-A259-26C0CAFA4BDA</gtr:id><gtr:impact>Joint patents with King's College London relating to tau phosphorylation in Alzheimer's disease.
Development of TMT methodology for quantitative proteomics.
Biomarker assays</gtr:impact><gtr:outcomeId>fG1zHTQnZMw</gtr:outcomeId><gtr:url>http://www.proteomics.com/products-and-services/cns/alzheimers-plasma-9-plex</gtr:url></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>A1566016-AA11-402C-9F6C-7155492DE124</gtr:id><gtr:title>Protocol for quantitative proteomics of cellular membranes and membrane rafts.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ea2b4141de2b0b21acbe1f462237306"><gtr:id>0ea2b4141de2b0b21acbe1f462237306</gtr:id><gtr:otherNames>Thompson AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>TixYMrrXMAq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CFB0AA2-F7AF-43CF-976B-45B2B59DBC15</gtr:id><gtr:title>Membrane-bound beta-amyloid oligomers are recruited into lipid rafts by a fyn-dependent mechanism.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f05f3699937eccf81187ac3689c1dad"><gtr:id>0f05f3699937eccf81187ac3689c1dad</gtr:id><gtr:otherNames>Williamson R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn><gtr:outcomeId>A7C9467E424</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89ACF3E6-DF3D-4035-BB26-3337B5A1E564</gtr:id><gtr:title>Isolation of detergent resistant microdomains from cultured neurons: detergent dependent alterations in protein composition.</gtr:title><gtr:parentPublicationTitle>BMC neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f05f3699937eccf81187ac3689c1dad"><gtr:id>0f05f3699937eccf81187ac3689c1dad</gtr:id><gtr:otherNames>Williamson R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1471-2202</gtr:issn><gtr:outcomeId>WKLXqNUgry4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8141F36E-0373-45E0-A518-2FE2E00D42E0</gtr:id><gtr:title>Advances in tau-based drug discovery.</gtr:title><gtr:parentPublicationTitle>Expert opinion on drug discovery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6181eaa28be814c0816a3195a16c5e23"><gtr:id>6181eaa28be814c0816a3195a16c5e23</gtr:id><gtr:otherNames>Noble W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1746-0441</gtr:issn><gtr:outcomeId>RkaZ4qY8vHK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A191AC0E-778C-4805-B6CC-925D5AD53F85</gtr:id><gtr:title>Functional implications of glycogen synthase kinase-3-mediated tau phosphorylation.</gtr:title><gtr:parentPublicationTitle>International journal of Alzheimer's disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03fdb5d2f4810671899a9cfd187a984a"><gtr:id>03fdb5d2f4810671899a9cfd187a984a</gtr:id><gtr:otherNames>Hanger DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>mdmFKwGzFP1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F6E9C45-5129-4FD9-85B0-7D10B258D52D</gtr:id><gtr:title>Direct analysis of tau from PSP brain identifies new phosphorylation sites and a major fragment of N-terminally cleaved tau containing four microtubule-binding repeats.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68ca09ebb1473b9780612d7b5d9dafef"><gtr:id>68ca09ebb1473b9780612d7b5d9dafef</gtr:id><gtr:otherNames>Wray S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn><gtr:outcomeId>1841D86DAB9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55606662-7828-4AA6-9443-4711BB2A3C60</gtr:id><gtr:title>Key issues in the acquisition and analysis of qualitative and quantitative mass spectrometry data for peptide-centric proteomic experiments.</gtr:title><gtr:parentPublicationTitle>Amino acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ea2b4141de2b0b21acbe1f462237306"><gtr:id>0ea2b4141de2b0b21acbe1f462237306</gtr:id><gtr:otherNames>Thompson AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0939-4451</gtr:issn><gtr:outcomeId>pm_13628_28_22821266</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7E94DFF-95C3-41B2-B6E6-D1915ADFB634</gtr:id><gtr:title>Quantitation of glycogen synthase kinase-3 sensitive proteins in neuronal membrane rafts.</gtr:title><gtr:parentPublicationTitle>Proteomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ea2b4141de2b0b21acbe1f462237306"><gtr:id>0ea2b4141de2b0b21acbe1f462237306</gtr:id><gtr:otherNames>Thompson AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1615-9853</gtr:issn><gtr:outcomeId>CED79A9D919</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400050</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>